$0.75
0.0%
Downside
Day's Volatility :8.42%
Upside
8.42%
1.33%
Downside
52 Weeks Volatility :37.82%
Upside
36.97%
Period | Rapid Micro Biosystems Inc | |
---|---|---|
3 Months | -18.21% | |
6 Months | -26.72% | |
1 Year | -21.39% | |
3 Years | -96.22% |
Market Capitalization | 35.1M |
Book Value | $2.48 |
Earnings Per Share (EPS) | -1.28 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.75 |
Profit Margin | -224.73% |
Operating Margin TTM | -254.38% |
Return On Assets TTM | -23.24% |
Return On Equity TTM | -40.17% |
Revenue TTM | 23.1M |
Revenue Per Share TTM | 0.54 |
Quarterly Revenue Growth YOY | 11.4% |
Gross Profit TTM | -8.5M |
EBITDA | -53.1M |
Diluted Eps TTM | -1.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.27 |
EPS Estimate Next Year | -1.14 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 533.33%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 16.5M | ↑ 50.56% |
Net Income | -21.2M | - |
Net Profit Margin | -128.22% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 16.1M | ↓ 2.63% |
Net Income | -37.1M | ↑ 75.14% |
Net Profit Margin | -230.63% | ↓ 102.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 23.2M | ↑ 44.5% |
Net Income | -73.5M | ↑ 98.3% |
Net Profit Margin | -316.48% | ↓ 85.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 17.1M | ↓ 26.25% |
Net Income | -60.8M | ↓ 17.3% |
Net Profit Margin | -354.91% | ↓ 38.43% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 22.5M | ↑ 31.44% |
Net Income | -52.5M | ↓ 13.71% |
Net Profit Margin | -232.99% | ↑ 121.92% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.4M | ↓ 7.7% |
Net Income | -16.4M | ↑ 0.66% |
Net Profit Margin | -376.02% | ↓ 31.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.0M | ↑ 15.11% |
Net Income | -13.9M | ↓ 15.57% |
Net Profit Margin | -275.81% | ↑ 100.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.0M | ↓ 0.66% |
Net Income | -14.0M | ↑ 0.93% |
Net Profit Margin | -280.21% | ↓ 4.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.1M | ↑ 22.85% |
Net Income | -13.4M | ↓ 4.45% |
Net Profit Margin | -217.93% | ↑ 62.28% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 6.3M | ↑ 3.12% |
Net Income | -11.2M | ↓ 16.58% |
Net Profit Margin | -176.3% | ↑ 41.63% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 5.6M | ↓ 11.46% |
Net Income | -13.3M | ↑ 19.24% |
Net Profit Margin | -237.43% | ↓ 61.13% |
FY11 | Y/Y Change | |
---|---|---|
Total Assets | 1.7M | ↓ 28.29% |
Total Liabilities | 6.8M | ↑ 36.12% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 31.7M | ↑ 1805.47% |
Total Liabilities | 32.4M | ↑ 374.15% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 70.0M | ↑ 120.89% |
Total Liabilities | 45.2M | ↑ 39.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 241.2M | ↑ 244.54% |
Total Liabilities | 20.2M | ↓ 55.31% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 190.7M | ↓ 20.95% |
Total Liabilities | 26.5M | ↑ 31.17% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 143.5M | ↓ 24.76% |
Total Liabilities | 25.5M | ↓ 3.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 190.7M | ↓ 5.58% |
Total Liabilities | 26.5M | ↑ 15.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 173.3M | ↓ 9.11% |
Total Liabilities | 20.8M | ↓ 21.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 160.9M | ↓ 7.12% |
Total Liabilities | 21.3M | ↑ 2.3% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 150.2M | ↓ 6.7% |
Total Liabilities | 22.4M | ↑ 4.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 143.5M | ↓ 4.47% |
Total Liabilities | 25.5M | ↑ 13.79% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 127.7M | ↓ 10.96% |
Total Liabilities | 21.8M | ↓ 14.43% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.1M | - |
Investing Cash Flow | -1.7M | - |
Financing Cash Flow | 14.9M | ↑ 396.99% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.0M | ↑ 46.57% |
Investing Cash Flow | -15.7M | ↑ 824.48% |
Financing Cash Flow | 64.2M | ↑ 331.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -55.0M | ↑ 77.33% |
Investing Cash Flow | -13.3M | ↓ 15.19% |
Financing Cash Flow | 216.7M | ↑ 237.43% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -58.5M | ↑ 6.52% |
Investing Cash Flow | -93.5M | ↑ 603.36% |
Financing Cash Flow | 693.0K | ↓ 99.68% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.7M | ↓ 22.84% |
Investing Cash Flow | 13.5M | ↑ 5.23% |
Financing Cash Flow | 87.0K | ↓ 42.38% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.7M | ↑ 43.17% |
Investing Cash Flow | 13.5M | ↑ 0.0% |
Financing Cash Flow | 122.0K | ↑ 40.23% |
Sell
Neutral
Buy
Rapid Micro Biosystems Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Bain Capital Life Sciences Investors, LLC
Kennedy Lewis Management LP
Glenview Capital Management LLC
ABG-WTT Global Life Science Capital Partners GP Ltd
BlackRock Inc
JPMorgan Chase & Co
rapid micro biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. the company's growth direct(tm) system detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. the growth direct(tm) system is the first and only automated system that accelerates testing while fitting with current regulatory practices and addressing all key applications.
Organization | Rapid Micro Biosystems Inc |
Employees | 193 |
CEO | Mr. Robert G. Spignesi Jr. |
Industry | Healthcare |